Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Announces Warrant Extension

GlobeNewswire November 4, 2024

Algernon Pharmaceuticals Announces Closing of Private Placement

GlobeNewswire August 20, 2024

Algernon Pharmaceuticals Announces Increase to Private Placement

GlobeNewswire August 13, 2024

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire August 7, 2024

Algernon Pharmaceuticals Announces Closing of Private Placement

GlobeNewswire August 2, 2024

Algernon Pharmaceuticals Announces Increase to Private Placement

GlobeNewswire July 31, 2024

Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

GlobeNewswire July 16, 2024

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire July 11, 2024

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

GlobeNewswire May 21, 2024

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 - 8th, 2024

GlobeNewswire April 24, 2024

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

GlobeNewswire April 11, 2024

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

GlobeNewswire April 1, 2024

Canadian Investment Regulatory Organization Trade Resumption - AGN

Canada NewsWire March 27, 2024

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

GlobeNewswire March 27, 2024

Canadian Investment Regulatory Organization Trading Halt - AGN

Canada NewsWire March 27, 2024

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

GlobeNewswire January 31, 2024

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

GlobeNewswire January 11, 2024

Algernon Pharmaceuticals Announces Closing of Private Placement

GlobeNewswire December 27, 2023

Algernon Pharmaceuticals Announces Increase to Private Placement

GlobeNewswire December 27, 2023

Algernon Pharmaceuticals Announces Private Placement

GlobeNewswire December 12, 2023